The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN acute myelogenous leukemia practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version].Rockledge, PA: National Comprehensive Cancer Network; 2001.
2.
TallmanM.S.Therapy of acute myeloid leukemia.Cancer Control.2001; 8: 62–78.
3.
RoweJ.M.What is the best induction regimen for acute myelogenous leukemia?Leukemia.1998; 12(suppl 1): S16–9.
4.
WeilM., GlidewellO.J., JacquillatC.Daunorubicin in the therapy of acute granulocytic leukemia.Cancer Res.1973; 33: 921–8.
5.
EllisonR.R., HollandJ.F., WeilM.Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults.Blood.1968; 32: 507–23.
6.
YatesJ.W., WallaceH.J., EllisonR.R.Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.Cancer Chemother Rep.1973; 57: 485–8.
7.
RaiK.R., HollandJ.F., GlidewellO.J.Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B.Blood.1981; 58: 1203–12.
8.
YatesJ., GlidewellO., WiernikP.Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study.Blood.1982; 60: 454–62.
9.
PreislerH., DavisR.B., KirschnerJ.Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study.Blood.1987; 69: 1441–9.
10.
DillmanR.O., DavisR.B., GreenM.R.A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B.Blood.1991; 78: 2520–6.
11.
ArlinZ., CaseD.C., MooreJ.Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL).Leukemia.1990; 4: 177–83.
12.
VoglerW.R., Velez-GarciaE., WeinerR.S.A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study group study.J Clin Oncol.1992; 10: 1103–11.
13.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
14.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
15.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version].Rockledge, PA: National Comprehensive Cancer Network; 2001.
16.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
19.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–9, 63–7,70–4.
20.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49: 1796–9.
21.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75: 397–402.
22.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
23.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–90.
